Patents by Inventor Karl Kunzelmann

Karl Kunzelmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230009145
    Abstract: The present invention relates to a compound for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof. The present invention further relates to a composition for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof.
    Type: Application
    Filed: December 9, 2020
    Publication date: January 12, 2023
    Inventors: KARL KUNZELMANN, RAINER SCHREIBER, BJÖRN BUCHHOLZ
  • Publication number: 20220206013
    Abstract: The present invention relates to a method of determining the effectiveness of a compound in a subject for treatment of cystic fibrosis comprising the steps of a) determining a first excretion level of bicarbonate in a first urine sampling obtained from a subject having cystic fibrosis; where said first urine sampling has been obtained prior to said subject has been treated with a compound for treatment of cystic fibrosis; b) determining a second excretion level of bicarbonate in a second urine sampling from said subject; where said second urine sampling is obtained after said subject has been treated with said compound for a predetermined time period; and c) determining the effectiveness of the compound against cystic fibrosis by comparing said first excretion level of bicarbonate to said second excretion level of bicarbonate; wherein said compound is considered as effective if said second excretion level of bicarbonate is above said first excretion level of bicarbonate and said compound is considered ineffec
    Type: Application
    Filed: May 6, 2020
    Publication date: June 30, 2022
    Inventors: Jens Georg Leipziger, Karl Kunzelmann, Peder Berg
  • Publication number: 20210283110
    Abstract: The present invention relates to a compound for use in a method of treating a disease selected from cystic fibrosis, ulcerative colitis, and irritable bowel syndrome, wherein said compound is an inhibitor of a TMEM16 protein, preferably of TMEM16A and/or TMEM16F.
    Type: Application
    Filed: October 10, 2019
    Publication date: September 16, 2021
    Inventor: KARL KUNZELMANN
  • Patent number: 7217571
    Abstract: A method for gene therapy using small fragment homologous replacement. The method introduces small fragments of exogenous DNA into regions of endogenous genomic DNA virtually homologous to the exogenous DNA. The exogenous DNA fragments contains sequence modification that correct mutations in the endogenous DNA or introduce mutations that alter cellular or an infecting pathogen phenotype.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: May 15, 2007
    Assignee: The Regents of the University of California
    Inventors: Deiter C. Gruenert, Karl Kunzelmann
  • Patent number: 6010908
    Abstract: A method for gene therapy using small fragment homologous replacement. The method introduces small fragments of exogenous DNA into regions of endogenous genomic DNA virtually homologous to the exogenous DNA. The exogenous DNA fragments contains sequence modification that correct mutations in the endogenous DNA or introduce mutations that alter cellular or an infecting pathogen phenotype.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignee: The Regents of the University of California
    Inventors: Deiter C. Gruenert, Karl Kunzelmann